Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma 3Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Diffuse Large B-Cell Lymphoma Refractory 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 130Methotrexate 93fludarabine phosphate 74Cytarabine 71Vincristine 66Whole-Body Irradiation 65Mycophenolic Acid 58Dexamethasone 55Tacrolimus 49Peripheral Blood Stem Cell Transplantation 48fludarabine 47Busulfan 46pegaspargase 43Filgrastim 41Etoposide 41Doxorubicin 41Calcium Dobesilate 40Granulocyte Colony-Stimulating Factor 39Rituximab 36Cyclosporine 36Mercaptopurine 35Melphalan 33Prednisone 31merphos 28Clofarabine 26Asparaginase 26Antilymphocyte Serum 25Leucovorin 23Daunorubicin 23Thiotepa 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Precursor Cell Lymphoblastic Leukemia-Lymphoma × loncastuximab tesirine × Clear all
NCT02669264 2021-05-24

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

ADC Therapeutics S.A.

Phase 1 Terminated
35 enrolled 31 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡